Chimeric Cyanovirin-MPER recombinantly engineered proteins cause cell-free virolysis of HIV-1. 2013

Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
Drexel University College of Medicine, Department of Biochemistry and Molecular Biology, Philadelphia, Pennsylvania, USA.

Human immunodeficiency virus (HIV) is the primary etiologic agent responsible for the AIDS pandemic. In this work, we used a chimeric recombinant protein strategy to test the possibility of irreversibly destroying the HIV-1 virion using an agent that simultaneously binds the Env protein and viral membrane. We constructed a fusion of the lectin cyanovirin-N (CVN) and the gp41 membrane-proximal external region (MPER) peptide with a variable-length (Gly4Ser)x linker (where x is 4 or 8) between the C terminus of the former and N terminus of the latter. The His-tagged recombinant proteins, expressed in BL21(DE3)pLysS cells and purified by immobilized metal affinity chromatography followed by gel filtration, were found to display a nanomolar efficacy in blocking BaL-pseudotyped HIV-1 infection of HOS.T4.R5 cells. This antiviral activity was HIV-1 specific, since it did not inhibit cell infection by vesicular stomatitis virus (VSV) or amphotropic-murine leukemia virus. Importantly, the chimeric proteins were found to release intraviral p24 protein from both BaL-pseudotyped HIV-1 and fully infectious BaL HIV-1 in a dose-dependent manner in the absence of host cells. The addition of either MPER or CVN was found to outcompete this virolytic effect, indicating that both components of the chimera are required for virolysis. The finding that engaging the Env protein spike and membrane using a chimeric ligand can destabilize the virus and lead to inactivation opens up a means to investigate virus particle metastability and to evaluate this approach for inactivation at the earliest stages of exposure to virus and before host cell encounter.

UI MeSH Term Description Entries
D010957 Plasmids Extrachromosomal, usually CIRCULAR DNA molecules that are self-replicating and transferable from one organism to another. They are found in a variety of bacterial, archaeal, fungal, algal, and plant species. They are used in GENETIC ENGINEERING as CLONING VECTORS. Episomes,Episome,Plasmid
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D001426 Bacterial Proteins Proteins found in any species of bacterium. Bacterial Gene Products,Bacterial Gene Proteins,Gene Products, Bacterial,Bacterial Gene Product,Bacterial Gene Protein,Bacterial Protein,Gene Product, Bacterial,Gene Protein, Bacterial,Gene Proteins, Bacterial,Protein, Bacterial,Proteins, Bacterial
D015202 Protein Engineering Procedures by which protein structure and function are changed or created in vitro by altering existing or synthesizing new structural genes that direct the synthesis of proteins with sought-after properties. Such procedures may include the design of MOLECULAR MODELS of proteins using COMPUTER GRAPHICS or other molecular modeling techniques; site-specific mutagenesis (MUTAGENESIS, SITE-SPECIFIC) of existing genes; and DIRECTED MOLECULAR EVOLUTION techniques to create new genes. Genetic Engineering of Proteins,Genetic Engineering, Protein,Proteins, Genetic Engineering,Engineering, Protein,Engineering, Protein Genetic,Protein Genetic Engineering
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015700 HIV Envelope Protein gp41 Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING. Envelope Protein gp41, HIV,HIV Transmembrane Protein gp41,HTLV-III gp41,env Protein gp41, HIV,gp41(HIV),gp41 Envelope Protein, HIV
D046529 Microscopy, Electron, Transmission Electron microscopy in which the ELECTRONS or their reaction products that pass down through the specimen are imaged below the plane of the specimen. Electron Diffraction Microscopy,Electron Microscopy, Transmission,Microscopy, Electron Diffraction,Transmission Electron Microscopy,Diffraction Microscopy, Electron,Microscopy, Transmission Electron

Related Publications

Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
January 2019, Acta naturae,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
November 2002, Clinical immunology (Orlando, Fla.),
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
January 2013, PloS one,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
January 2013, PloS one,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
July 1994, AIDS research and human retroviruses,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
November 2020, Virology,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
July 1993, AIDS research and human retroviruses,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
April 2018, The Journal of biological chemistry,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
July 2020, Annals of biomedical engineering,
Mark Contarino, and Arangassery R Bastian, and Ramalingam Venkat Kalyana Sundaram, and Karyn McFadden, and Caitlin Duffy, and Vamshi Gangupomu, and Michelle Baker, and Cameron Abrams, and Irwin Chaiken
August 2011, Advanced functional materials,
Copied contents to your clipboard!